MIDATECH PHARMA
Investors

Welcome to the Investor Relations pages for Midatech Pharma PLC

Midatech is an international specialty pharmaceutical company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need.

Midatech is commercialising oncology treatment and supportive care products via its US Commercial Organisation, Midatech Pharma US. In Europe, Midatech is advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of Cancer, Endocrine Disorders such as Diabetes, and Immunotherapy for autoimmune diseases.

Midatech’s strategy is to expand it US commercial arm as well as develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.

Midatech Pharma Group is incorporated in England and Wales, with global headquarters in the United Kingdom and a fully integrated commercial subsidiary based in the United States.

Midatech’s ordinary shares are traded on the Alternative Investment Market (AIM) of the London Stock Exchange under the ticker symbol MTPH (ISIN number GB00BRTL9B63). Midatech’s American Depositary Shares trade on the NASDAQ Capital Market in the United States under the symbol MTP (CUSIP No. 59564R 104).

The information disclosed in these pages is in accordance with Rule 26 of the Aim Rules. The investor site was most recently updated on 1 May 2016.

 

FAQ

On which exchange are Midatech shares traded and what is the ticker symbol?

Midatech’s ordinary shares are traded on the Alternative Investment Market (AIM) of the London Stock Exchange under the ticker symbol MTPH (ISIN number GB00BRTL9B63), and NASDAQ.

Midatech’s American Depositary Shares trade on the NASDAQ Capital Market in the United States under the symbol MTP (CUSIP No. 59564R 104). Each American Depositary Share represents two ordinary shares.


Where is Midatech incorporated?

Midatech Pharma PLC is incorporated in England and Wales (registered number 04097593).


Where are Midatech’s corporate headquarters?

Midatech is headquartered in Oxfordshire, UK.


Can I purchase shares directly from the company?

No, Midatech does not have a direct stock purchase plan. Shares may be purchased through a financial services provider of your choice.


Can I replace lost ordinary share certificates?

A new share warrant or coupon may be issued in the place of one damaged, defaced, worn out or lost (provided that no new share warrant shall be issued to replace one that has been lost unless the Board is satisfied beyond reasonable doubt that the original has been destroyed).


Does Midatech pay a dividend?

Not at this point in time.

How can I get a copy of your Annual Report or any other Investor materials (i.e. regulatory announcements, financial calendar)?

All annual and Interim reports are posted in the Investors section of our website under “Reports and Presentations” along with other useful materials for investors.


What are American Depositary Receipts (ADRs)?

The stocks of most foreign companies that trade in the U.S. markets are traded as American Depositary Receipts (ADRs). U.S. depositary banks issue these stocks. Each ADR represents one or more shares of foreign stock or a fraction of a share. If you own an ADR, you have the right to obtain the foreign stock it represents, but U.S. investors usually find it more convenient to own the ADR. The price of an ADR corresponds to the price of the foreign stock in its home market, adjusted to the ratio of the ADRs to foreign company shares. Securities of a foreign company that are represented by an ADR are called American depositary shares (ADSs).


Why issue ADRs?

The advantages of ADRs are twofold. For individuals, ADRs are an easy and cost-effective way to buy shares in a foreign company. They save money by reducing administration costs and avoiding foreign taxes on each transaction. Foreign entities like ADRs because they get more U.S. exposure, allowing them to tap into the wealthy North American equities markets.


What types of ADR programs exist and which type does Midatech Pharma have?

There are three different types of ADR issues:


There are three types of ADR program (see below). Midatech Pharma has a Level 3 ADR program which trades on NASDAQ (ticker: MTP):


Level 1 - This is the most basic type of ADR aimed at non-U.S. companies that either don't qualify or don't wish to have their ADR listed on a U.S. stock exchange. Level 1 ADRs trade on the U.S. over-the-counter market and are an easy and inexpensive way for a company to gauge interest for its securities in the U.S.



Level 2 - This type of ADR program is listed on a U.S. stock exchange and therefore requires the issuer to adhere fully with the 2002 Sarbanes-Oxley Act, but this additional disclosure and regulation often results in greater visibility, trading volume and investor interest.



Level 3 – Like a Level 2 ADR program, a Level 3 ADR program is also listed on a U.S. stock exchange but also involves a capital-raising event in the form of ADRs. This is the ADR program that Midatech Pharma established in December 2015

How can I find further information about Midatech Pharma ADRs?

Midatech Pharma’s ADR program is administered by Deutsche Bank Trust Company Americas.
Please visit: http://www.adr.db.com


Contact details for institutional ADR investors and brokers:

New York: +1 212 250 9100

London: +44 207 547 6500


Contact details for registered ADR holders:

Deutsche Bank Shareholder Services

American Stock Transfer & Trust Company

Operations Center

6201 15th Avenue

Brooklyn, NY 11219

Email: DB@amstock.com

Toll free number: (866) 249 2593 (if calling from within the U.S.)

Direct Dial: +1 718 921 8124 (if calling from outside the U.S.)


What if I owned DARA BioSciences, Inc. common stock certificates prior to the merger with Midatech?

Under the terms of the merger agreement between Midatech and DARA BioSciences, Inc., DARA stockholders received (i) 0.272 Midatech ordinary shares plus (ii) one contingent value right, which represents the right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the terms and conditions of the contingent value rights agreement between the parties. All ordinary shares issued in connection with the merger were delivered in the form of American Depositary Receipts, each representing the right to receive two ordinary shares.

Investors

Welcome to the Investor Relations pages for Midatech Pharma PLC

Midatech is an international specialty pharmaceutical company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need.

Midatech is commercialising oncology treatment and supportive care products via its US Commercial Organisation, Midatech Pharma US. In Europe, Midatech is advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of Cancer, Endocrine Disorders such as Diabetes, and Immunotherapy for autoimmune diseases.

Midatech’s strategy is to expand it US commercial arm as well as develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.

Midatech Pharma Group is incorporated in England and Wales, with global headquarters in the United Kingdom and a fully integrated commercial subsidiary based in the United States.

Midatech’s ordinary shares are traded on the Alternative Investment Market (AIM) of the London Stock Exchange under the ticker symbol MTPH (ISIN number GB00BRTL9B63). Midatech’s American Depositary Shares trade on the NASDAQ Capital Market in the United States under the symbol MTP (CUSIP No. 59564R 104).

The information disclosed in these pages is in accordance with Rule 26 of the Aim Rules. The investor site was most recently updated on 1 May 2016.

 

FAQ

On which exchange are Midatech shares traded and what is the ticker symbol?

Midatech’s ordinary shares are traded on the Alternative Investment Market (AIM) of the London Stock Exchange under the ticker symbol MTPH (ISIN number GB00BRTL9B63), and NASDAQ.

Midatech’s American Depositary Shares trade on the NASDAQ Capital Market in the United States under the symbol MTP (CUSIP No. 59564R 104). Each American Depositary Share represents two ordinary shares.


Where is Midatech incorporated?

Midatech Pharma PLC is incorporated in England and Wales (registered number 04097593).


Where are Midatech’s corporate headquarters?

Midatech is headquartered in Oxfordshire, UK.


Can I purchase shares directly from the company?

No, Midatech does not have a direct stock purchase plan. Shares may be purchased through a financial services provider of your choice.


Can I replace lost ordinary share certificates?

A new share warrant or coupon may be issued in the place of one damaged, defaced, worn out or lost (provided that no new share warrant shall be issued to replace one that has been lost unless the Board is satisfied beyond reasonable doubt that the original has been destroyed).


Does Midatech pay a dividend?

Not at this point in time.

How can I get a copy of your Annual Report or any other Investor materials (i.e. regulatory announcements, financial calendar)?

All annual and Interim reports are posted in the Investors section of our website under “Reports and Presentations” along with other useful materials for investors.


What are American Depositary Receipts (ADRs)?

The stocks of most foreign companies that trade in the U.S. markets are traded as American Depositary Receipts (ADRs). U.S. depositary banks issue these stocks. Each ADR represents one or more shares of foreign stock or a fraction of a share. If you own an ADR, you have the right to obtain the foreign stock it represents, but U.S. investors usually find it more convenient to own the ADR. The price of an ADR corresponds to the price of the foreign stock in its home market, adjusted to the ratio of the ADRs to foreign company shares. Securities of a foreign company that are represented by an ADR are called American depositary shares (ADSs).


Why issue ADRs?

The advantages of ADRs are twofold. For individuals, ADRs are an easy and cost-effective way to buy shares in a foreign company. They save money by reducing administration costs and avoiding foreign taxes on each transaction. Foreign entities like ADRs because they get more U.S. exposure, allowing them to tap into the wealthy North American equities markets.


What types of ADR programs exist and which type does Midatech Pharma have?

There are three different types of ADR issues:


There are three types of ADR program (see below). Midatech Pharma has a Level 3 ADR program which trades on NASDAQ (ticker: MTP):


Level 1 - This is the most basic type of ADR aimed at non-U.S. companies that either don't qualify or don't wish to have their ADR listed on a U.S. stock exchange. Level 1 ADRs trade on the U.S. over-the-counter market and are an easy and inexpensive way for a company to gauge interest for its securities in the U.S.



Level 2 - This type of ADR program is listed on a U.S. stock exchange and therefore requires the issuer to adhere fully with the 2002 Sarbanes-Oxley Act, but this additional disclosure and regulation often results in greater visibility, trading volume and investor interest.



Level 3 – Like a Level 2 ADR program, a Level 3 ADR program is also listed on a U.S. stock exchange but also involves a capital-raising event in the form of ADRs. This is the ADR program that Midatech Pharma established in December 2015

How can I find further information about Midatech Pharma ADRs?

Midatech Pharma’s ADR program is administered by Deutsche Bank Trust Company Americas.
Please visit: http://www.adr.db.com


Contact details for institutional ADR investors and brokers:

New York: +1 212 250 9100

London: +44 207 547 6500


Contact details for registered ADR holders:

Deutsche Bank Shareholder Services

American Stock Transfer & Trust Company

Operations Center

6201 15th Avenue

Brooklyn, NY 11219

Email: DB@amstock.com

Toll free number: (866) 249 2593 (if calling from within the U.S.)

Direct Dial: +1 718 921 8124 (if calling from outside the U.S.)


What if I owned DARA BioSciences, Inc. common stock certificates prior to the merger with Midatech?

Under the terms of the merger agreement between Midatech and DARA BioSciences, Inc., DARA stockholders received (i) 0.272 Midatech ordinary shares plus (ii) one contingent value right, which represents the right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the terms and conditions of the contingent value rights agreement between the parties. All ordinary shares issued in connection with the merger were delivered in the form of American Depositary Receipts, each representing the right to receive two ordinary shares.

© Copyright 2017 Midatech Pharma PLC